X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA VENUS REMEDIES PLETHICO PHARMA/
VENUS REMEDIES
 
P/E (TTM) x -1.1 -3.7 - View Chart
P/BV x 0.0 0.1 12.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
VENUS REMEDIES
Mar-18
PLETHICO PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs395126 313.7%   
Low Rs3161 51.2%   
Sales per share (Unadj.) Rs604.4301.8 200.3%  
Earnings per share (Unadj.) Rs32.5-24.9 -130.6%  
Cash flow per share (Unadj.) Rs51.32.5 2,017.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.6293.3 161.5%  
Shares outstanding (eoy) m34.0812.34 276.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.3 113.8%   
Avg P/E ratio x6.6-3.8 -174.5%  
P/CF ratio (eoy) x4.236.7 11.3%  
Price / Book Value ratio x0.50.3 141.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2621,154 629.4%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m1,596393 406.0%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m20,5983,724 553.1%  
Other income Rs m38623 1,717.1%   
Total revenues Rs m20,9843,747 560.1%   
Gross profit Rs m2,818395 713.7%  
Depreciation Rs m642338 189.9%   
Interest Rs m1,593354 449.7%   
Profit before tax Rs m969-275 -351.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-13832 -437.9%   
Profit after tax Rs m1,107-307 -360.7%  
Gross profit margin %13.710.6 129.0%  
Effective tax rate %-14.3-11.5 124.5%   
Net profit margin %5.4-8.2 -65.2%  
BALANCE SHEET DATA
Current assets Rs m18,8772,638 715.7%   
Current liabilities Rs m11,8962,305 516.2%   
Net working cap to sales %33.98.9 379.0%  
Current ratio x1.61.1 138.6%  
Inventory Days Days36135 26.5%  
Debtors Days Days19846 427.0%  
Net fixed assets Rs m9,8614,871 202.4%   
Share capital Rs m341123 276.1%   
"Free" reserves Rs m12,3313,496 352.7%   
Net worth Rs m16,1393,619 445.9%   
Long term debt Rs m4,7061,374 342.4%   
Total assets Rs m33,1467,509 441.4%  
Interest coverage x1.60.2 721.1%   
Debt to equity ratio x0.30.4 76.8%  
Sales to assets ratio x0.60.5 125.3%   
Return on assets %8.10.6 1,290.4%  
Return on equity %6.9-8.5 -80.9%  
Return on capital %12.31.6 776.8%  
Exports to sales %21.40-   
Imports to sales %15.213.9 109.8%   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136517 607.1%   
Fx inflow Rs m4,4020-   
Fx outflow Rs m3,184517 616.4%   
Net fx Rs m1,219-517 -235.9%   
CASH FLOW
From Operations Rs m2,437514 473.8%  
From Investments Rs m-6,265-123 5,089.1%  
From Financial Activity Rs m2,490-387 -643.3%  
Net Cashflow Rs m-1,3374 -31,837.1%  

Share Holding

Indian Promoters % 82.7 32.9 251.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.2 2,388.9%  
FIIs % 5.5 0.6 948.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 66.4 11.3%  
Shareholders   10,665 20,121 53.0%  
Pledged promoter(s) holding % 85.7 36.4 235.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS